Biotech Values

[puravida]

Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”

As a result of the acquisition, the Company (i) paid an aggregate of $1,925,000 in cash, a portion of which was applied to retire outstanding obligations of Noachis Terra with the balance being paid to Mr. Hernandez, (ii) issued 9,200,000 shares of common stock of the Company and warrants to purchase 9,200,000 shares of common stock of the Company, carrying an exercise price of $1.25 per share and a five-year term,


https://ir.oragenics.com/press-releases/detail/104/oragenics-acquires-noachis-terra-inc-to-develop-its